1. Home
  2. CCCC vs AGEN Comparison

CCCC vs AGEN Comparison

Compare CCCC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • AGEN
  • Stock Information
  • Founded
  • CCCC 2015
  • AGEN 1994
  • Country
  • CCCC United States
  • AGEN United States
  • Employees
  • CCCC N/A
  • AGEN N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CCCC Health Care
  • AGEN Health Care
  • Exchange
  • CCCC Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • CCCC 304.8M
  • AGEN 286.0M
  • IPO Year
  • CCCC 2020
  • AGEN 2000
  • Fundamental
  • Price
  • CCCC $5.35
  • AGEN $15.05
  • Analyst Decision
  • CCCC Buy
  • AGEN Strong Buy
  • Analyst Count
  • CCCC 7
  • AGEN 2
  • Target Price
  • CCCC $8.71
  • AGEN $70.00
  • AVG Volume (30 Days)
  • CCCC 2.2M
  • AGEN 534.1K
  • Earning Date
  • CCCC 08-06-2024
  • AGEN 08-06-2024
  • Dividend Yield
  • CCCC N/A
  • AGEN N/A
  • EPS Growth
  • CCCC N/A
  • AGEN N/A
  • EPS
  • CCCC N/A
  • AGEN N/A
  • Revenue
  • CCCC $20,036,000.00
  • AGEN $161,416,000.00
  • Revenue This Year
  • CCCC $26.24
  • AGEN $43.78
  • Revenue Next Year
  • CCCC N/A
  • AGEN N/A
  • P/E Ratio
  • CCCC N/A
  • AGEN N/A
  • Revenue Growth
  • CCCC N/A
  • AGEN 69.94
  • 52 Week Low
  • CCCC $1.06
  • AGEN $4.78
  • 52 Week High
  • CCCC $11.88
  • AGEN $38.00
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 58.71
  • AGEN 54.27
  • Support Level
  • CCCC $4.36
  • AGEN $15.05
  • Resistance Level
  • CCCC $5.37
  • AGEN $16.12
  • Average True Range (ATR)
  • CCCC 0.33
  • AGEN 1.14
  • MACD
  • CCCC 0.13
  • AGEN -0.05
  • Stochastic Oscillator
  • CCCC 86.61
  • AGEN 44.11

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: